Abeona Therapeutics (ABEO) Q4 2024 earnings summary

Executive summary

• FDA priority review of PZ-cel BLA is ongoing, with a PDUFA date of April 29, 2025, and commercial launch preparations targeting first patient treatment in Q3 2025.

• Five major EB treatment centers are onboarding as qualified treatment centers (QTCs), with launch expected in Q3 2025 pending approval.

• PZ-cel is positioned as a transformative, first-in-class therapy for RDEB, with strong clinical data and high patient and physician enthusiasm.

• Expanded manufacturing capacity and secured additional patents for PZ-cel, extending protection to 2040.

• A partnered program with Ultragenyx for MPS IIIA is also under FDA priority review, with a PDUFA date of August 18, 2025.

Financial highlights

• Cash, cash equivalents, short-term investments, and restricted cash totaled $98.1 million as of December 31, 2024, up from $52.6 million at year-end 2023, supporting operations into 2026.

• Research and development expenses were $34.4 million for 2024, compared to $31.1 million in 2023, mainly due to manufacturing expansion.

• General administrative expenses rose to $29.9 million in 2024 from $19 million in 2023, mainly due to commercial launch preparations.

• Net loss for 2024 was $63.7 million ($1.55 per share), compared to $54.2 million ($2.53 per share) in 2023.

• Weighted average shares outstanding were 41.0 million in 2024, up from 21.4 million in 2023.

Outlook and guidance

• Launch of PZ-cel expected in Q3 2025, with gradual ramp-up in patient treatments and manufacturing capacity.

• Manufacturing capacity to increase from 4 to 10 treatments per month by early 2026, with long-term plans for 200+ annual treatments by H2 2027.

• Revenue recognition will occur upon administration of PZ-cel, with initial gradual uptake at QTCs.

• Ex-U.S. expansion is under consideration, with interest from Europe and Asia, but focus remains on U.S. launch.

• Sufficient liquidity to fund operations into 2026, excluding potential PZ-cel revenue or PRV proceeds.